PMID- 35570071
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221027
IS  - 1532-1681 (Electronic)
IS  - 0268-960X (Linking)
VI  - 56
DP  - 2022 Nov
TI  - Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia 
      - What to look for when treatment-free remission is not an option.
PG  - 100968
LID - S0268-960X(22)00042-X [pii]
LID - 10.1016/j.blre.2022.100968 [doi]
AB  - The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has 
      improved the prognosis of patients with chronic myeloid leukemia (CML). Although 
      there are some common class-wide side effects, differences in safety profiles 
      between TKIs allow physicians and patients to personalize treatment plans. 
      Treatment selection depends on several factors, such as age, disease risk, 
      comorbidities, and concomitant medications. In second- and later-line settings, 
      response to previous TKIs and mutation analyses should also be used to guide TKI 
      selection. Several strategies can be used to manage adverse events (AEs) that 
      emerge during treatment, e.g., dose reductions/interruptions, monitoring, 
      treatment of AEs, lifestyle modifications, prophylactic therapy, and other 
      supportive care strategies. This review summarizes the safety profiles of the 
      currently approved TKIs and how they impact treatment selection in the first- and 
      later-line settings of CML, particularly regarding patient comorbidities and 
      concomitant medications. Additionally, strategies to manage AEs of special 
      interest with TKIs are reviewed.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Lipton, Jeffrey H
AU  - Lipton JH
AD  - Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: 
      Jeff.Lipton@uhn.ca.
FAU - Brummendorf, Tim H
AU  - Brummendorf TH
AD  - Universitatsklinikum RWTH Aachen, Aachen, Germany.
FAU - Gambacorti-Passerini, Carlo
AU  - Gambacorti-Passerini C
AD  - University of Milano-Bicocca, Monza, Italy.
FAU - Garcia-Gutierrez, Valentin
AU  - Garcia-Gutierrez V
AD  - Servicio de Hematologia, Hospital Universitario Ramon y Cajal, Instituto Ramon y 
      Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain.
FAU - Deininger, Michael W
AU  - Deininger MW
AD  - Versiti Blood Research Institute, Milwaukee, WI, USA.
FAU - Cortes, Jorge E
AU  - Cortes JE
AD  - Division of Hematology and SCT, Georgia Cancer Center, Augusta, GA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220506
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - Protein Kinase Inhibitors/adverse effects
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/genetics
MH  - *Antineoplastic Agents/adverse effects
OTO - NOTNLM
OT  - Adverse events
OT  - Chronic myeloid leukemia
OT  - Long-term
OT  - Safety
OT  - Tyrosine kinase inhibitors
COIS- Declaration of Competing Interest Jeffrey Lipton: served as a consultant for 
      Bristol-Myers Squibb, Novartis, Pfizer, and Takeda; received research funding 
      from Bristol-Myers Squibb, Novartis, Pfizer, and Takeda; received honoraria from 
      Bristol-Myers Squibb, Novartis, Incyte, Pfizer and Takeda. Tim H Brummendorf: 
      consultant for Janssen, Merck, Novartis, Pfizer, and received research support 
      from Novartis and Pfizer. Carlo Gambacorti-Passerini: provides consultancy to 
      Bristol-Myers Squibb and received honoraria and research support from Pfizer. 
      Valentin Garcia-Gutierrez: served as a consultant for Bristol-Myers Squibb, 
      Incyte, Novartis and Pfizer; received research funding from Pfizer, Novartis, 
      Bristol-Myers Squibb and Incyte. Michael Deininger: served as a paid consultant 
      for Blueprint, Ariad, Blueprint Medicine, Bristol-Myers Squibb, Galena Biopharma, 
      Incyte, Novartis, Fusion Pharma, Sangamo and Pfizer; received research funding 
      from Bristol-Myers Squibb, Celgene, Gilead Sciences, Incyte, Novartis, SPARC, 
      DisperSol, Pfizer and Blueprint. Jorge E Cortes: served as a consultant for 
      Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, 
      Bristol-Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and 
      Takeda, and received research funding from Astellas Pharma, Bristol-Myers Squibb, 
      Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun 
      Pharma, Takeda, Tolero Pharmaceuticals and Tovagene.
EDAT- 2022/05/16 06:00
MHDA- 2022/10/26 06:00
CRDT- 2022/05/15 22:04
PHST- 2022/01/06 00:00 [received]
PHST- 2022/04/26 00:00 [revised]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/05/16 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
PHST- 2022/05/15 22:04 [entrez]
AID - S0268-960X(22)00042-X [pii]
AID - 10.1016/j.blre.2022.100968 [doi]
PST - ppublish
SO  - Blood Rev. 2022 Nov;56:100968. doi: 10.1016/j.blre.2022.100968. Epub 2022 May 6.